Emerging Topic Conference: The Genomics Revolution Evaluation
The conference will focus on genomics and the changing approach to diagnostics, management and research in adult and pediatric liver diseases. This course will provide a broad overview of genomic technologies and how they may be applied to understand the genetic underpinnings of rare and complex liver disorders. Attendees will develop a better understanding of the true genomic contribution to liver disease, and how this data can lead to personalized approaches to medical therapy.
How to access your CME Certificate from the Emerging Topic Conference: The Genomics Revolution 2019:
1. Log into LiverLearning®. Please remember to login with your AASLD username and password.
2. For ABIM or ABP MOC, ensure your ABIM ID and birthday (month/day) are in your LiverLearning® Profile. It is between “Home” and “My Dashboard” in the left navigation box. (Note: Once you update your Profile, click “Save” and then click the “Back” button in your web browser to get back into the activity.)
3. Scroll down to “Sessions and Evaluations” and click the link to begin the evaluation process.
4. Complete the overall conference experience evaluation. This step must be completed before moving forward to receive your Certificate of Attendance, claim CME and or claim ABIM or ABP MOC points.
5. Print your Certificate of Attendance. This is proof of attending the conference for your records.
6. Attest to EACH session you attended at the conference. You will simply click on the session you attended, attest and receive credit.
7. Once you have attested to sessions attended:
a. Click “View CME certificate” tab to return to the Emerging Topic Conference: The Genomics of Revolution Live Conference homepage to earn your ABIM or ABP MOC points; or
b. Retrieve your CME certificate. (Note: Credits earned will be applied to your cohesive CME Certificate comprising all sessions completed.)
8. Click the link in the “Maintenance of Certification” box to earn your ABIM or ABP MOC points.
9. Print your CME certificate at any time following the conference by clicking the CME Certificate box.
If you have any questions regarding the CME and or MOC process, please contact education@aasld.org. If you have any technical questions, please contact online_education@aasld.org.
Better understand how they can use genomic data to answer research questions.
Use genomic testing in the diagnosis and management of liver disease.
Get insight into the existing datasets that can be used in research and clinical care.
Hepatologists
Gastroenterologists
Surgeons
Fellows
Quentin M. Anstee, MBBS, PhD, FRCP
Laura Bull, PhD
Stephen L. Guthery, MD, MS
Steven Harrison, PhD
Gideon Hirschfield, FRCP, PhD
Binita M. Kamath, MBBChir
Saul J. Karpen, MD, PhD, FAASLD
Brendan James Keating, PhD
Kathleen M. Loomes, MD, FAASLD
Teri Manolio, MD, PhD
Merrie Mosedale, PhD
Justin L. Mott, MD, PhD
Lisa S. Parker, PhD
Nancy B. Spinner, PhD
Gyongyi Szabo, MD, PhD, FAASLD
Richard J. Thompson MD, PhD, FAASLD
Kimberly D. Tremblay, PhD
Silvia M. Vilarinho, MD, PhD
Catherine Williamson, PhD
Joseph Zabner, MD
This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Emerging Topic Conference faculty and the Clinical Research Committee and Governing Board.
As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.
Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device.
Financial disclosures will appear at the beginning of each session and are provided below
Faculty Disclosures
Quentin M. Anstee, MBBS, PhD, FRCP
Grants/Research Support: Abbvie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex
Scientific Consulting: Abbott Laboratories, Acuitas Medical, Allergan/Tobira, Blade, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Imperial Innovations, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Kenes, Madrigal, MedImmune, Metacrine, NewGene, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Servier, Viking Therapeutics
Laura Bull, PhD
Nothing to Disclose
Stephen L. Guthery, MD, MS
Nothing to Disclose
Steven Harrison, PhD
Nothing to Disclose
Gideon Hirschfield, FRCP, PhD
Scientific Consulting: Cymabay, Intercept, GSK, Novartis, Gilead
Binita M. Kamath, MBBChir
Scientific Consulting: Shire, Mirum, DCI
Saul J. Karpen, MD, PhD, FAASLD
Scientific Consulting: Intercept Pharmaceuticals, Retrophin, LogicBio, Albireo
Brendan James Keating, PhD
Nothing to Disclose
Kathleen M. Loomes, MD, FAASLD
Leadership in Related Society: NASPGHAN Research Committee, NASPGHAN Nominating Committee
Grants/Research Support: NIH, Shire, Albireo
Teri Manolio, MD, PhD
Nothing to Disclose
Merrie Mosedale, PhD
Nothing to Disclose
Justin L. Mott, MD, PhD
Nothing to Disclose
Lisa S. Parker, PhD
Nothing to Disclose
Nancy B. Spinner, PhD
Nothing to Disclose
Gyongyi Szabo, MD, PhD, FAASLD
Grants/Research Support: NIH-NIAAA, Shire, Gilead, Genfit
Richard J. Thompson MD, PhD, FAASLD
Scientific Consulting: Shire, Albireo, GenerationBio
Stock/Stock Options: GenerationBio
Kimberly D. Tremblay, PhD
Nothing to Disclose
Silvia M. Vilarinho, MD, PhD
Nothing to Disclose
Catherine Williamson, PhD
Nothing to Disclose
Joseph Zabner, MD
Nothing to Disclose
Planner Disclosures
Meena B. Bansal, MD, FAASLD (Governing Board)
Nothing to disclose
Jorge A. Bezerra, MD, FAASLD (Governing Board)
Grant/Research Support: Shyer, Gilead
Mamatha Bhat (Clinical Research Committee)
Nothing to disclose
Therese Bittermann, MD (Clinical Research Committee)
Nothing to disclose
Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
Nothing to disclose
Raymond Chung, MD, FAASLD (Governing Board)
Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
Other: DSMB – Alnylam
Laurie DeLeve, MD, PhD, FAASLD (Governing Board)
Consulting: Daiichi Sankyo; Seagen; Pfizer
Edward Doo, MD (Clinical Research Committee)
Nothing to disclose
Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
Grants/Research Support: BMS, Gilead, Abbvie
Consulting: Sanofi
Kimberly A Forde, MD, MHS (Clinical Research Committee)
Nothing to disclose
Michael W. Fried, MD, FAASLD (Governing Board)
Stock/Stock Options: TARGET PharmaSolutions
Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health
Paul Yien Kwo, MD, FAASLD (Clinical Research Committee)
Consulting: Gilead, Abbvie
Grants/Research Support: BMS, Abbvie
John R. Lake, MD, FAASLD (Governing Board)
Consulting: Vital Therapies, SRTR
Other: Intercept DSMB
Jennifer Cindy Lai, MD (Clinical Research Committee)
Consulting: Third Rock Ventures, LLC, Axcella
Rohit Loomba, MD (Clinical Research Committee)
Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc
Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
Board Membership: ACG Research Committee, Baxalta, DSMB
Consulting: National Hemophilia Foundation
Lopa Mishra, MD, FAASLD (Governing Board)
Grant/Research Support: NIH
David C. Mulligan, MD, FAASLD (Governing Board)
Nothing to disclose
Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
Nothing to disclose
Ronald J. Sokol, MD, FAASLD (Governing Board)
Consulting: Alexion; Albireo; Retrophin; Shire
Grant/Research Support: Lumena/Shire; FFF Enterprises
Shikha Sundaram, MD, MSCI (Clinical Research Committee)
Nothing to disclose
Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
Advisory Committees and or Review Panels: Dova
Grant/Research Support: AbbVie, Gilead, BMS, Merck
Kymberly Watt, MD (Clinical Research Committee)
Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related
Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals
AASLD Staff Disclosures
Heather Carnahan
Nothing to disclose
Julie Deal
Nothing to disclose
Sharon Grant
Nothing to disclose
Janeil Klett
Nothing to disclose
Denise Seise
Nothing to disclose
Suzanne Thibeault
Nothing to disclose
Anne Wrobel
Nothing to disclose
Continuing Medical Education (CME)
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
American Board of Pediatrics Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 9.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC points.
